Both Hospira, Inc., the manufacturer of sodium thiopental, and Lundbeck,
Inc., the manufacturer of pentobarbital, have publicly stated that they sent letters to state departments of corrections condemning the use of their product in executions
by lethal injection. In Lundbeck?s case, the company?s concern was based on serious concerns regarding the efficacy of the drug for such use. Certainly, concerns over the efficacy of a drug, which is intended to be the most crucial aspect of the three drug sequence is an indication of a flaw in the procedures.